Treatment with High Dose Rifampicin in Tuberculous Meningitis: A Case Report

Retno J Ketaren, Vonny Goenawan, Jennifer Simca

Abstract


Introduction : Tuberculous meningitis continues to be associated with considerable mortality and morbidity.A randomized comparison of higher-dose intravenous rifampicin (approximately 13 mg/kg per day) versus a standard oral dose in adults with tuberculous meningitis showed that mortality among patients who received higher intravenous dose was 50% lower than those who received the standard dose.1 While there are other contradictory results regarding the use of high-dose rifampicin in patients with tuberculous meningitis.

Method  : We hereby report a case of a 20-year-old female patient presented with a history of fever, palpable neck lymph nodes and headache since 1 month before admission. Neurological examination revealed nuchal rigidity without other neurological deficits. Head MRI  with contrast showed meningitis with tuberculoma in the right parietal lobe +/- 0.4 cm and neck ultrasonography showed multiple lymphadenopathy with 1 cm in diameter. Cerebrospinal fluid examination revealed tuberculous meningitis. The patient had been treated with rifampicin 450 mg, other tuberculosis regiments, levofloxacin, and dexamethasone. After one week of treatment, the patient developed generalized seizure and deterioration of consciousness. Imaging re-evaluation showed multiple acute infarction in the cortical and subcortical left frontal lobe, bilateral insula, bilateral temporal lobe, right parietal lobe to the corpus callosum, more prominent leptomeningeal contrast, and communicating hydrocephalus. Ventriculoperitoneal shunt was done. The patient was then treated with a higher dose of Rifampicin (15 mg/kg ~ 900 mg) and showed improvement after 2 weeks of treatment without any abnormal laboratory findings.

Conclusion   : The usage of high dose rifampicin is still controversial. From this case we can conclude that by giving high dose rifampicin, the patient has a better outcome without any significant side effects. Thus, we support the hypothesis of using high-dose rifampicin in  patients with tuberculous meningitis that does not respond to the standard treatment.


Keywords


High-dose rifampicin, tuberculous meningitis, communicating hydrocephalus



DOI: http://dx.doi.org/10.19166/med.v7i4.2387

Full Text:

PDF

References


Zumla A, Raviglione M, Hafner R, von Reyn CF. Current concepts: tuberculosis. N Engl J Med 2013;368:745–755

World Health Organization. Global tuberculosis report 2013. Available at: http://www.who.int/tb/publications/global_report/en/index.html. Accessed April 8,2018.

Ruslami R, Ganiem AR, Dian S, et al. Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial. Lancet Infect Dis 2013;13:27-35.

Chin JH. Tuberculous meningitis: Diagnostic and Therapeutic Challenges. Neurol Clin Pract. 2014 Jun; 4(3): 199-205.

Yunivita V, Dian S, Ganiem AR, Hayati E, Hanggono Achmad T, Purnama Dewi A, et al. Pharmacokinetics and safety/tolerability of higher oral and intravenous doses of rifampicin in adult tuberculous meningitis patients. Int J Antimicrob Agents. 2016 Oct; 48(4): 415-421.


Refbacks

  • There are currently no refbacks.


Copyright (c) 2020 Retno J Ketaren, Vonny Goenawan, Jennifer Simca

Creative Commons License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

 

Creative Commons License

MEDICINUS is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. Copyright © Fakultas Kedokteran | Universitas Pelita Harapan | Lippo Karawaci, Tangerang, Indonesia, 15811 . All rights reserved. p-ISSN 1978-3094 | e-ISSN 2622-6995